Ernesto MejÃ-as-PÃ©rez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4889406/publications.pdf

Version: 2024-02-01

16 papers	948 citations	759233 12 h-index	940533 16 g-index
17 all docs	17 docs citations	17 times ranked	1615 citing authors

#	Article	IF	Citations
1	Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nature Medicine, 2022, 28, 496-503.	30.7	215
2	Rapid, efficient and activation-neutral gene editing of polyclonal primary human resting CD4+ T cells allows complex functional analyses. Nature Methods, 2022, 19, 81-89.	19.0	12
3	Neutrophil subtypes shape HIV-specific CD8 T-cell responses after vaccinia virus infection. Npj Vaccines, 2021, 6, 52.	6.0	6
4	MicroRNAs are minor constituents of extracellular vesicles that are rarely delivered to target cells. PLoS Genetics, 2021, 17, e1009951.	3.5	125
5	The Envelope-Based Fusion Antigen GP120C14K Forming Hexamer-Like Structures Triggers T Cell and Neutralizing Antibody Responses Against HIV-1. Frontiers in Immunology, 2019, 10, 2793.	4.8	2
6	Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR-Î”4 with a Set of Gene Deletions on Several Viral Pathways. Molecular Therapy - Oncolytics, 2018, 8, 27-40.	4.4	22
7	Distinct Roles of Vaccinia Virus NF-ÎºB Inhibitor Proteins A52, B15, and K7 in the Immune Response. Journal of Virology, 2017, 91, .	3.4	31
8	A Prime/Boost PfCS14K^M/MVA-sPfCS^MVaccination Protocol Generates Robust CD8⁺T Cell and Antibody Responses to Plasmodium falciparum Circumsporozoite Protein and Protects Mice against Malaria. Vaccine Journal, 2017, 24, .	3.1	10
9	Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells. Nature Communications, 2017, 8, 16073.	12.8	222
10	Modification of promoter spacer length in vaccinia virus as a strategy to control the antigen expression. Journal of General Virology, 2015, 96, 2360-2371.	2.9	14
11	NFÎºB activation by modified vaccinia virus as a novel strategy to enhance neutrophil migration and HIV-specific T-cell responses. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1333-E1342.	7.1	26
12	The Evolution of Poxvirus Vaccines. Viruses, 2015, 7, 1726-1803.	3.3	164
13	Virological and Immunological Characterization of Novel NYVAC-Based HIV/AIDS Vaccine Candidates Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as Virus-Like Particles. Journal of Virology, 2015, 89, 970-988.	3.4	30
14	New vaccinia virus promoter as a potential candidate for future vaccines. Journal of General Virology, 2013, 94, 2771-2776.	2.9	22
15	Attenuated and Replication-Competent Vaccinia Virus Strains M65 and M101 with Distinct Biology and Immunogenicity as Potential Vaccine Candidates against Pathogens. Journal of Virology, 2013, 87, 6955-6974.	3.4	14
16	High Quality Long-Term CD4+ and CD8+ Effector Memory Populations Stimulated by DNA-LACK/MVA-LACK Regimen in Leishmania major BALB/c Model of Infection. PLoS ONE, 2012, 7, e38859.	2.5	30